DeepMed Research

IPSEN, OOO

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

Active, not recruiting

Conditions: Advanced Renal Cell Carcinoma

First Posted Date: 2022-05-04

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 311

Registration Number: NCT05361434

Locations: 🇧🇪
CHU St Pierre & Brugmann, Bruxelles, Belgium
🇧🇪
Jessa Ziekenhuis, Hasselt, Belgium
🇧🇪
CHU Namur Mont-Godinne, Yvoir, Belgium

and more 63 locations

Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.

Active, not recruiting

Conditions: Post-Stroke Chronic Upper Limb Spasticity

First Posted Date: 2022-02-04

Last Posted Date: 2025-04-30

Lead Sponsor: Ipsen

Target Recruit Count: 121

Registration Number: NCT05224349

Locations: 🇩🇪
Nervenarztpraxis, Altdorf, Germany
🇩🇪
Herford; Klinikum Herford, Herford, Germany
🇩🇪
Neurologisches Zentrum, Berlin, Germany

and more 27 locations

Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China

Withdrawn

Conditions: Acromegaly

First Posted Date: 2022-01-11

Last Posted Date: 2023-03-17

Lead Sponsor: Ipsen

Registration Number: NCT05184231

A Single Centre, Prospective, Observational Study to Assess the Use of the Rehabilitation Tool, GripAble, in Patients With Upper Limb Spasticity Receiving Botulinum Toxin-A (BoNT-A) in the United Kingdom (UK).

Completed

Conditions: Upper Limb Spasticity (ULS)

First Posted Date: 2021-12-27

Last Posted Date: 2023-01-27

Lead Sponsor: Ipsen

Target Recruit Count: 16

Registration Number: NCT05169775

Locations: 🇬🇧
Hull University Teaching Hospital NHS Trust, Hull, United Kingdom

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Phase 3

Completed

Conditions: Central Precocious Puberty

Interventions: Drug: Triptorelin Pamoate

First Posted Date: 2021-08-31

Last Posted Date: 2025-02-19

Lead Sponsor: Ipsen

Target Recruit Count: 66

Registration Number: NCT05029622

Locations: 🇨🇳
Children's Hospital of Fudan University, Changhai, China
🇨🇳
Pingxiang Maternity and Child Care, Pingxiang, China
🇨🇳
Chengdu Women's & Children's Central Hospital, Chengdu, China

and more 11 locations

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

Phase 3

Completed

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)

Interventions: Drug: Palovarotene

First Posted Date: 2021-08-30

Last Posted Date: 2024-12-27

Lead Sponsor: Ipsen

Target Recruit Count: 63

Registration Number: NCT05027802

Locations: 🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Children's Hospital of Philidelphia, Philadelphia, Pennsylvania, United States

and more 10 locations

A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Biological: Botulinum toxin type A

First Posted Date: 2021-07-21

Last Posted Date: 2025-02-19

Lead Sponsor: Ipsen

Target Recruit Count: 45

Registration Number: NCT04970407

Locations: 🇬🇧
Mac Research Clinical research Unit, Manchester, United Kingdom

Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

Completed

Conditions: Advanced Renal Cell Carcinoma (aRCC)

First Posted Date: 2021-07-12

Last Posted Date: 2024-12-17

Lead Sponsor: Ipsen

Target Recruit Count: 281

Registration Number: NCT04957160

Locations: 🇬🇧
Barts Cancer Institute, London, United Kingdom
🇬🇧
Royal Surrey County Hospital, Guildford, United Kingdom
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

and more 6 locations

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.

Phase 4

Active, not recruiting

Conditions: Upper Limb Spasticity

Interventions: Biological: AboBoNT-A
Biological: OnaBoNT-A

First Posted Date: 2021-06-23

Last Posted Date: 2025-04-30

Lead Sponsor: Ipsen

Target Recruit Count: 464

Registration Number: NCT04936542

Locations: 🇨🇦
Victoria General Hospital, Victoria, Canada
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States

and more 73 locations

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Phase 3

Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumor

Interventions: Drug: Lanreotide autogel

First Posted Date: 2021-04-21

Last Posted Date: 2024-09-30

Lead Sponsor: Ipsen

Target Recruit Count: 43

Registration Number: NCT04852679

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Sciences, Beijing, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy